Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Abbott bags European...

    Abbott bags European nod for Tendyne Transcatheter Mitral Valve Implantation system

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-01T13:00:45+05:30  |  Updated On 16 Aug 2021 4:10 PM IST
    Abbott bags European nod for Tendyne Transcatheter Mitral Valve Implantation system

    New Delhi: Abbott today announced that its Tendyne Transcatheter Mitral Valve Implantation (TMVI) system received CE Mark and is now approved for use in Europe. This life-changing therapy treats significant mitral regurgitation (MR) in patients requiring a heart valve replacement and provides a safe and effective solution for MR patients who are not candidates for open-heart surgery or transcatheter mitral valve repair.

    As the most common heart disease affecting the heart valves, MR is a debilitating, progressive and life-threatening condition in which the heart's mitral valve does not close completely, allowing blood to flow backwards into the left atrium of the heart. Due to the complex nature of mitral valve disease and different patient anatomies, multiple treatment options for MR may be necessary. For patients at high-risk for open-heart surgery or in clinical situations when the mitral valve is too damaged for a successful repair with Abbott's MitraClip device, the Tendyne system offers a much-needed, alternative minimally invasive treatment option when the leaky valve needs to be replaced.

    The Abbott Tendyne valve is a first-of-its-kind therapy to replace the mitral valve in patients in need of symptom relief and quality-of-life improvement without open surgery and when a transcatheter mitral repair is not possible. Global trial results to date have demonstrated excellent procedural safety and have shown 98.9% of Tendyne patients experienced MR elimination at discharge which was sustained through one-year in this very sick patient group.

    Also Read: Twin Approvals: Abbott Bags CE Mark For Its Mechanical Heart Valve And Occluder Devices

    "European approval for Abbott's Tendyne mitral valve replacement therapy provides the clinical community with a new choice in how we approach correcting a leaking mitral valve," said Hendrik Treede, M.D., professor of cardiac surgery, University Hospital Bonn, Germany. "For the first time outside of clinical trial settings, heart teams now have a minimally invasive valve replacement therapy that is backed by an excellent safety profile and designed to help physicians reposition the device as needed for improved patient outcomes." A post-approval study of the therapy will also be co-led by Nicolas Dumonteil, M.D., interventional cardiologist, Clinique Pasteur, France.

    The Tendyne TMVI system can adapt to a range of patient anatomies thanks to its innovative and unique design. The self-expanding valve is delivered through a small incision in the chest and up through the heart where it is implanted in a beating heart, replacing the person's native mitral valve. The Tendyne valve is available in multiple sizes to treat a broad range of valve anatomies. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people suffering from MR and needing a valve replacement.

    "The launch of the Tendyne device builds upon our history of developing groundbreaking therapies that offer new treatment options for people with serious structural heart conditions who have limited treatment options," said Michael Dale, senior vice president of Abbott's structural heart business. "The availability of Tendyne as a treatment option in Europe provides physicians with an additional tool that has been shown to completely correct MR in very ill patients, and it adds to Abbott's portfolio of life-changing and life-saving treatments."

    Abbott is the global leader in developing transcatheter mitral valve technologies as alternatives to open-heart surgery. Building upon its success with the MitraClip device and many years of mitral valve experience and clinical evidence, Abbott is leading the way in novel, transcatheter devices by investing in the development and clinical study of minimally invasive technologies.

    Also Read: Abbott Gets USFDA Nod For Less-Invasive Surgical Approach For Heart Pump

    abbottTendyne Transcatheter Mitral Valve Implantationtranscatheter valvemedical devicesTMVIimplantation system

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok